References
- Stamp LK, Day RO, Yun J. Allopurinol hypersensitivity: investigating the cause and minimizing the risk. Nat Rev Rheumatol. 2016. 12(4):235–242. Erratum in: Nat Rev Rheumatol. 2016 Apr;12(4):i. PMID: 26416594. doi:10.1038/nrrheum.2015.132
- Russell MD, Yates M, Bechman K, et al. Rising incidence of acute hospital admissions due to gout. J Rheumatol. 2020;47(4):619–623. PMID: 31523046. doi:10.3899/jrheum.190257
- Bellón T. Mechanisms of severe cutaneous adverse reactions: recent advances. Drug Saf. 2019;42(8):973–992. PMID: 31020549. doi:10.1007/s40264-019-00825-2
- Yun J, Mattsson J, Schnyder K, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exper Allergy. 2013;43(43):1246–1255. doi:10.1111/cea.12184
- Ferdiana A, Fachiroh J, Oktarina DAM, et al. Allopurinol-induced Stevens-Johnson Syndrome in Javanese Men With Positive HLA-B*58:01. Front Genet. 2022;13:839154. PMID: 35769987; PMCID: PMC9234807. doi:10.3389/fgene.2022.839154
- Low DE, Nurul-Aain AF, Tan WC, et al. HLA-B*58: 01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia. Pharmacogenet Genomics. 2020;30(7):153–160. PMID: 32433341. doi:10.1097/FPC.0000000000000408
- Su SC, Chung WH. Cytotoxic proteins and therapeutic targets in severe cutaneous adverse reactions. Toxins. 2014;6(1):194–210. doi:10.3390/toxins6010194
- Wang F, Ma Z, Wu X, Liu L. Allopurinol-induced toxic epidermal necrolysis featuring almost 60% skin detachment. Medicine. 2019;98(25):e16078. doi:10.1097/MD.0000000000016078
- Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245. doi:10.1038/clpt.1981.154
- Sachs B, Fatangare A, Sickmann A, Glässner A. Lymphocyte transformation test: history and current approaches. J Immunol Methods. 2021;493:113036. doi:10.1016/j.jim.2021.113036
- Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149–153. doi:10.1046/j.1523
- Do MD, Mai TP, Do AD, et al. Risk factors for cutaneous reactions to allopurinol in Kinh Vietnamese: results from a case-control study. Arthritis Res Ther. 2020;22(182). doi:10.1186/s13075-020-02273-1
- Zimmermann S, Sekula P, Venhoff M, et al. Systemic immunomodulating therapies for Stevens-Johnson Syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2017;153(6):514–522. PMID: 28329382; PMCID: PMC5817620. doi:10.1001/jamadermatol.2016.5668
- Guerrero-Putz MD, Gomez-Flores M, Ocampo-Candiani J, Alba-Rojas E. Bacteremia in Stevens Johnson Syndrome and toxic epidermal necrolysis: main pathogens and risk factors: a mini review. Austin J Dermatolog. 2021;8(2):1099.
- Hung CC, Liu WC, Kuo MC, Lee CH, Hwang SJ, Chen HC. Acute renal failure and its risk factors in Stevens-Johnson Syndrome and toxic epidermal necrolysis. Am J Nephrol. 2009;29(6):633–638. doi:10.1159/000195632
- FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res. 2020;72(6):744–760. PubMed 32391934. doi:10.1002/acr.24180